SG10201508159SA - Factor II And Fibrinogen For Treatment Of Haemostatic Disorders - Google Patents
Factor II And Fibrinogen For Treatment Of Haemostatic DisordersInfo
- Publication number
- SG10201508159SA SG10201508159SA SG10201508159SA SG10201508159SA SG10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA
- Authority
- SG
- Singapore
- Prior art keywords
- fibrinogen
- factor
- treatment
- haemostatic disorders
- haemostatic
- Prior art date
Links
- 108010049003 Fibrinogen Proteins 0.000 title 1
- 102000008946 Fibrinogen Human genes 0.000 title 1
- 108010094028 Prothrombin Proteins 0.000 title 1
- 229940030225 antihemorrhagics Drugs 0.000 title 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 title 1
- 229940012952 fibrinogen Drugs 0.000 title 1
- 230000000025 haemostatic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39022410P | 2010-10-06 | 2010-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201508159SA true SG10201508159SA (en) | 2015-10-29 |
Family
ID=44677879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201508159SA SG10201508159SA (en) | 2010-10-06 | 2011-09-19 | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
| SG2013021498A SG188639A1 (en) | 2010-10-06 | 2011-09-19 | Factor ii and fibrinogen for treatment of haemostatic disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013021498A SG188639A1 (en) | 2010-10-06 | 2011-09-19 | Factor ii and fibrinogen for treatment of haemostatic disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9433664B2 (enExample) |
| EP (1) | EP2624859B1 (enExample) |
| JP (1) | JP6000259B2 (enExample) |
| KR (1) | KR20130136988A (enExample) |
| CN (1) | CN103221061A (enExample) |
| AU (1) | AU2011313505B2 (enExample) |
| BR (1) | BR112013008034A2 (enExample) |
| CA (1) | CA2812888A1 (enExample) |
| DK (1) | DK2624859T3 (enExample) |
| ES (1) | ES2625153T3 (enExample) |
| HU (1) | HUE033204T2 (enExample) |
| MX (1) | MX343784B (enExample) |
| PL (1) | PL2624859T3 (enExample) |
| RU (1) | RU2606155C2 (enExample) |
| SG (2) | SG10201508159SA (enExample) |
| WO (1) | WO2012045569A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12171463B2 (en) | 2008-10-03 | 2024-12-24 | Femasys Inc. | Contrast agent generation and injection system for sonographic imaging |
| SG10201508159SA (en) | 2010-10-06 | 2015-10-29 | Medimmune Ltd | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
| IL230150A0 (en) * | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing zymogens |
| JP7227905B2 (ja) | 2017-02-09 | 2023-02-22 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血の処置または予防における使用のための血液凝固因子代替製品 |
| CN116059431A (zh) * | 2021-10-29 | 2023-05-05 | 丁琴琴 | 一种含凝血因子的双层止血敷料及其制备方法 |
| WO2023220412A1 (en) * | 2022-05-13 | 2023-11-16 | Cedars-Sinai Medical Center | Hemostatic monitor |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3165600D1 (en) | 1980-01-28 | 1984-09-27 | Baxter Travenol Lab | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
| US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
| DE4430204A1 (de) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
| HUP9700603A3 (en) | 1996-03-20 | 2001-08-28 | Baxter Ag | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| US7094428B2 (en) | 2000-06-16 | 2006-08-22 | The University Of Medicine And Dentistry Of New Jersey | Hemostatic compositions, devices and methods |
| US6825323B2 (en) | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
| ATE386538T1 (de) | 2001-02-05 | 2008-03-15 | Novo Nordisk Healthcare Ag | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden |
| US20060025336A1 (en) | 2001-07-16 | 2006-02-02 | Novo Nordisk A/S | Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides |
| AU2002354846B2 (en) | 2001-07-20 | 2007-08-02 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
| US20040101546A1 (en) * | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
| EP1587424A4 (en) | 2002-12-31 | 2012-01-25 | Marinepolymer Tech Inc | Bleeding Compounds and their uses |
| GB0324044D0 (en) | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| EP1748781B1 (en) | 2004-05-27 | 2012-12-19 | Baxter International Inc. | Methods for treating bleeding disorders using sulfated polysaccharides |
| EP1893230A2 (en) | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| MX2008006313A (es) | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| CA2644926A1 (en) * | 2006-03-06 | 2007-09-13 | Humagene, Inc. | A method for the preparation of recombinant human thrombin and fibrinogen |
| US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
| WO2008051513A2 (en) | 2006-10-23 | 2008-05-02 | Allan Pronovost | Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
| EP1935429A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
| US20080267940A1 (en) | 2007-03-30 | 2008-10-30 | Mohammed Syed F | Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue |
| NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| US8852558B2 (en) | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
| EP2337793A4 (en) | 2008-10-08 | 2013-04-10 | Thrombodyne Inc | METHOD FOR PRODUCING CONCENTRATED FIBRINOGEN AND PLAIN-CONTAINING COMPOSITIONS |
| SG10201508159SA (en) | 2010-10-06 | 2015-10-29 | Medimmune Ltd | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
-
2011
- 2011-09-19 SG SG10201508159SA patent/SG10201508159SA/en unknown
- 2011-09-19 SG SG2013021498A patent/SG188639A1/en unknown
- 2011-09-19 ES ES11761051.9T patent/ES2625153T3/es active Active
- 2011-09-19 BR BR112013008034A patent/BR112013008034A2/pt not_active IP Right Cessation
- 2011-09-19 EP EP11761051.9A patent/EP2624859B1/en not_active Revoked
- 2011-09-19 JP JP2013532104A patent/JP6000259B2/ja not_active Expired - Fee Related
- 2011-09-19 KR KR1020137008520A patent/KR20130136988A/ko not_active Ceased
- 2011-09-19 RU RU2013120033A patent/RU2606155C2/ru not_active IP Right Cessation
- 2011-09-19 PL PL11761051T patent/PL2624859T3/pl unknown
- 2011-09-19 DK DK11761051.9T patent/DK2624859T3/en active
- 2011-09-19 US US13/877,854 patent/US9433664B2/en not_active Expired - Fee Related
- 2011-09-19 CA CA2812888A patent/CA2812888A1/en not_active Abandoned
- 2011-09-19 HU HUE11761051A patent/HUE033204T2/en unknown
- 2011-09-19 WO PCT/EP2011/066241 patent/WO2012045569A1/en not_active Ceased
- 2011-09-19 CN CN2011800479754A patent/CN103221061A/zh active Pending
- 2011-09-19 AU AU2011313505A patent/AU2011313505B2/en not_active Ceased
- 2011-09-19 MX MX2013003715A patent/MX343784B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011313505A1 (en) | 2013-04-11 |
| DK2624859T3 (en) | 2017-06-06 |
| WO2012045569A1 (en) | 2012-04-12 |
| CN103221061A (zh) | 2013-07-24 |
| AU2011313505B2 (en) | 2015-09-17 |
| US9433664B2 (en) | 2016-09-06 |
| MX2013003715A (es) | 2013-09-26 |
| JP2013538863A (ja) | 2013-10-17 |
| WO2012045569A9 (en) | 2016-01-07 |
| JP6000259B2 (ja) | 2016-09-28 |
| HUE033204T2 (en) | 2017-11-28 |
| EP2624859B1 (en) | 2017-03-01 |
| RU2013120033A (ru) | 2014-11-20 |
| ES2625153T3 (es) | 2017-07-18 |
| US20130280236A1 (en) | 2013-10-24 |
| EP2624859A1 (en) | 2013-08-14 |
| SG188639A1 (en) | 2013-05-31 |
| KR20130136988A (ko) | 2013-12-13 |
| CA2812888A1 (en) | 2012-04-12 |
| MX343784B (es) | 2016-11-23 |
| RU2606155C2 (ru) | 2017-01-10 |
| PL2624859T3 (pl) | 2017-09-29 |
| BR112013008034A2 (pt) | 2016-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261768B (en) | Devices and methods for tissue treatment | |
| EP2603202A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES | |
| ZA201304280B (en) | Treatment of jak2-mediated conditions | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| IL225130A (en) | Devices for treating blood vessels defects | |
| SG10201602789XA (en) | Corticosteroids for the treatment of joint pain | |
| ZA201205829B (en) | Treatment of respiratory disorders | |
| ZA201301601B (en) | Treatment of diseases | |
| ZA201303810B (en) | Methods and compositions suitable for promoting healthy skin | |
| IL215592A0 (en) | Compositions and methods for the treatment of inflammation | |
| EP2574172A4 (en) | MATERIALS AND METHOD FOR TREATING INFLAMMATION | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| IL225793A0 (en) | Methods and preparations for curing insulin-related medical conditions | |
| IL225896A0 (en) | Treatment of mecp-2 related disorders | |
| HUE038787T2 (hu) | Tripeptid készítmények és alkalmazásuk diabétesz kezelésére | |
| ZA201301936B (en) | Methods and compositions for treatment of diabetes and dyslipidemia | |
| IL256026B (en) | Treatment methods | |
| EP2566483A4 (en) | METHOD AND MEANS FOR IMPROVED WOUND HEALING | |
| SG10201508159SA (en) | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders | |
| SG10201510568WA (en) | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions | |
| IL223385B (en) | Treatment of inflammatory disorders | |
| GB201010638D0 (en) | Composition for treatment of skin | |
| GB201007205D0 (en) | Treatment of joint disorders | |
| GB201002500D0 (en) | Treatment of burns | |
| GB201012310D0 (en) | Composition for the treatment of botulism |